Standout Papers

A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors 2021 2026 2022 2024206
  1. A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors (2021)
    Jia Zhou, Camille Gelot et al. Nature Cancer

Immediate Impact

5 by Nobel laureates 15 from Science/Nature 53 standout
Sub-graph 1 of 24

Citing Papers

Past, present, and future of CRISPR genome editing technologies
2024 Standout
Development of Aptamer-DNAzyme based metal-nucleic acid frameworks for gastric cancer therapy
2024 Standout
2 intermediate papers

Works of Hatice Yücel being referenced

A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors
2021 Standout
EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation
2017

Author Peers

Author Last Decade Papers Cites
Hatice Yücel 478 347 31 83 5 560
Anbazhagan Rajendran 446 314 54 98 7 562
Maddison Rose 337 341 72 43 7 558
Jung‐Sik Kim 391 358 58 130 6 559
Cecilia Ström 414 312 24 43 10 505
Connor S. Clairmont 541 267 22 71 13 596
Marta Castroviejo‐Bermejo 277 379 83 66 3 482
Camille Gelot 422 201 15 40 11 485
Shannon L. Gibson 412 229 42 47 7 533
Nicholas Jette 427 283 50 42 6 514
Samuel E. Jones 432 201 35 34 8 505

All Works

Loading papers...

Rankless by CCL
2026